Brooklyn ImmunoTherapeutics (NYSE:BTX) Earns Hold Rating from Analysts at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a report issued on Tuesday. The firm set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Stock Performance

Shares of Brooklyn ImmunoTherapeutics stock opened at $0.25 on Tuesday. The company has a market capitalization of $14.71 million, a PE ratio of -0.11 and a beta of 4.61. The company has a 50-day simple moving average of $0.71 and a two-hundred day simple moving average of $1.33. Brooklyn ImmunoTherapeutics has a one year low of $0.17 and a one year high of $10.10.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.